Genenta Logo.png
Genenta Appoints Four Renowned Oncology Experts to Scientific Advisory Board
May 17, 2021 04:33 ET | Genenta Science
MILAN, Italy and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta Logo.png
Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon™ Delivered Tumor-Focused Interferon Expression
May 14, 2021 01:30 ET | Genenta Science
MILAN, Italy and NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of an investigational hematopoietic stem progenitor...
Genenta Logo.png
Genenta to present at upcoming scientific congresses
May 10, 2021 01:30 ET | Genenta Science
MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta Logo.png
Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member
May 03, 2021 01:30 ET | Genenta Science
MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta Logo.png
Genenta to Take Part in Gene Therapy Panel and Two Virtual Investor Events in January 2021
January 05, 2021 08:49 ET | Genenta Science
MILAN, Italy and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...
Genenta Logo.png
Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman
November 23, 2020 01:00 ET | Genenta Science
MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy...
Genenta Logo.png
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
November 16, 2020 01:00 ET | Genenta Science
MILAN, Italy and NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...
Genenta Logo.png
Genenta to present preliminary Phase I/II clinical data on Temferon™ in glioblastoma multiforme at Chardan’s 4th Annual Genetic Medicines Conference
September 30, 2020 08:51 ET | Genenta Science
MILAN, Italy and NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer...